351 related articles for article (PubMed ID: 26077975)
1. Platelet Activation Markers Are Associated with Crohn's Disease Activity in Patients with Low C-Reactive Protein.
Takeyama H; Mizushima T; Iijima H; Shinichiro S; Uemura M; Nishimura J; Hata T; Takemasa I; Yamamoto H; Doki Y; Mori M
Dig Dis Sci; 2015 Nov; 60(11):3418-23. PubMed ID: 26077975
[TBL] [Abstract][Full Text] [Related]
2. Association of clinical and inflammatory markers with small bowel capsule endoscopy findings in Crohn's disease.
Mitselos IV; Katsanos KH; Tatsioni A; Skamnelos A; Eliakim R; Tsianos EV; Christodoulou DK
Eur J Gastroenterol Hepatol; 2018 Aug; 30(8):861-867. PubMed ID: 29697457
[TBL] [Abstract][Full Text] [Related]
3. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI.
Schoepfer AM; Beglinger C; Straumann A; Trummler M; Vavricka SR; Bruegger LE; Seibold F
Am J Gastroenterol; 2010 Jan; 105(1):162-9. PubMed ID: 19755969
[TBL] [Abstract][Full Text] [Related]
4. Plateletcrit: a sensitive biomarker for evaluating disease activity in Crohn's disease with low hs-CRP.
Tang J; Gao X; Zhi M; Zhou HM; Zhang M; Chen HW; Yang QF; Liang ZZ
J Dig Dis; 2015 Mar; 16(3):118-24. PubMed ID: 25565427
[TBL] [Abstract][Full Text] [Related]
5. Slight increases in the disease activity index and platelet count imply the presence of active intestinal lesions in C-reactive protein-negative Crohn's disease patients.
Nakarai A; Kato J; Hiraoka S; Inokuchi T; Takei D; Morito Y; Akita M; Takahashi S; Hori K; Harada K; Okada H; Yamamoto K
Intern Med; 2014; 53(17):1905-11. PubMed ID: 25175121
[TBL] [Abstract][Full Text] [Related]
6. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial.
Peyrin-Biroulet L; Reinisch W; Colombel JF; Mantzaris GJ; Kornbluth A; Diamond R; Rutgeerts P; Tang LK; Cornillie FJ; Sandborn WJ
Gut; 2014 Jan; 63(1):88-95. PubMed ID: 23974954
[TBL] [Abstract][Full Text] [Related]
7. Combined evaluation of biomarkers as predictor of maintained remission in Crohn's disease.
Sollelis E; Quinard RM; Bouguen G; Goutte M; Goutorbe F; Bouvier D; Pereira B; Bommelaer G; Buisson A
World J Gastroenterol; 2019 May; 25(19):2354-2364. PubMed ID: 31148906
[TBL] [Abstract][Full Text] [Related]
8. Selected biologic markers of inflammation and activity of Crohn's disease.
Karczewski J; Swora-Cwynar E; Rzymski P; Poniedziałek B; Adamski Z
Autoimmunity; 2015; 48(5):318-27. PubMed ID: 25707687
[TBL] [Abstract][Full Text] [Related]
9. CD4+ immune response as a potential biomarker of patient reported inflammatory bowel disease (IBD) activity.
Brandhorst G; Weigand S; Eberle C; Raddatz D; Karaus M; Oellerich M; Walson PD
Clin Chim Acta; 2013 Jun; 421():31-3. PubMed ID: 23485644
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic value of C-reactive protein for predicting activity level of Crohn's disease.
Chamouard P; Richert Z; Meyer N; Rahmi G; Baumann R
Clin Gastroenterol Hepatol; 2006 Jul; 4(7):882-7. PubMed ID: 16630759
[TBL] [Abstract][Full Text] [Related]
11. C-reactive protein and monitoring the activity of Crohn's disease.
Filik L; Dagli U; Ulker A
Adv Ther; 2006; 23(4):655-62. PubMed ID: 17050508
[TBL] [Abstract][Full Text] [Related]
12. Inflammatory mediators and acute phase proteins in patients with Crohn's disease and ulcerative colitis.
Niederau C; Backmerhoff F; Schumacher B; Niederau C
Hepatogastroenterology; 1997; 44(13):90-107. PubMed ID: 9058126
[TBL] [Abstract][Full Text] [Related]
13. Neutrophil-lymphocyte ratio: a controversial marker in predicting Crohn's disease severity.
Gao SQ; Huang LD; Dai RJ; Chen DD; Hu WJ; Shan YF
Int J Clin Exp Pathol; 2015; 8(11):14779-85. PubMed ID: 26823804
[TBL] [Abstract][Full Text] [Related]
14. Red cell distribution width for assessment of activity of inflammatory bowel disease.
Cakal B; Akoz AG; Ustundag Y; Yalinkilic M; Ulker A; Ankarali H
Dig Dis Sci; 2009 Apr; 54(4):842-7. PubMed ID: 18716874
[TBL] [Abstract][Full Text] [Related]
15. Correlation of Paraoxonase-1 with the Severity of Crohn's Disease.
Szczeklik K; Mach T; Cibor D; Owczarek D; Sapa J; Papież M; Pytko-Polończyk J; Krzyściak W
Molecules; 2018 Oct; 23(10):. PubMed ID: 30314292
[TBL] [Abstract][Full Text] [Related]
16. Impaired coronary microvascular and left ventricular diastolic function in patients with inflammatory bowel disease.
Caliskan Z; Gokturk HS; Caliskan M; Gullu H; Ciftci O; Ozgur GT; Guven A; Selcuk H
Microvasc Res; 2015 Jan; 97():25-30. PubMed ID: 25128749
[TBL] [Abstract][Full Text] [Related]
17. A phase 2 study of allogeneic mesenchymal stromal cells for luminal Crohn's disease refractory to biologic therapy.
Forbes GM; Sturm MJ; Leong RW; Sparrow MP; Segarajasingam D; Cummins AG; Phillips M; Herrmann RP
Clin Gastroenterol Hepatol; 2014 Jan; 12(1):64-71. PubMed ID: 23872668
[TBL] [Abstract][Full Text] [Related]
18. Serum calprotectin as a biomarker for Crohn's disease.
Meuwis MA; Vernier-Massouille G; Grimaud JC; Bouhnik Y; Laharie D; Piver E; Seidel L; Colombel JF; Louis E;
J Crohns Colitis; 2013 Dec; 7(12):e678-83. PubMed ID: 23845231
[TBL] [Abstract][Full Text] [Related]
19. Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC.
Ferrante M; Colombel JF; Sandborn WJ; Reinisch W; Mantzaris GJ; Kornbluth A; Rachmilewitz D; Lichtiger S; D'Haens GR; van der Woude CJ; Danese S; Diamond RH; Oortwijn AF; Tang KL; Miller M; Cornillie F; Rutgeerts PJ;
Gastroenterology; 2013 Nov; 145(5):978-986.e5. PubMed ID: 23954314
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the relationship between serum ghrelin, C-reactive protein and interleukin-6 levels, and disease activity in inflammatory bowel diseases.
Cekic C; Arabul M; Alper E; Pakoz ZB; Saritas E; Yuksel ; Ünsal B
Hepatogastroenterology; 2014; 61(133):1196-200. PubMed ID: 25436282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
